Richard Owusu Ansah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard Owusu Ansah has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- James Opoku Frimpong
Department of Clinical Microbiology, College of Health Sciences, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana
2 shared publications - Nana Kwame Ayisi-Boateng
Kwame Nkrumah University of Science and Technology
2 shared publications - Richard Larbi
Genomic and Infectious Diseases Laboratory, Department of Medical Diagnostics, Faculty of Allied Health, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
2 shared publications - Ama Darkoaa Sarfo
Pediatric Infectious Disease Unit, Child Health Directorate, Komfo Anokye Teaching Hospital, Kumasi, Ghana
1 shared publication - Anthony Kwame Enimil
Komfo Anokye Teaching Hospital (KATH), Kumasi P.O. Box KS 1934, Ghana
1 shared publication - Augustina Angelina Sylverken
Department of Theoretical and Applied Biology, Kwame Nkrumah University of Science and Technology, University Post Office, Private Mail Bag, Kumasi 00233, Ghana
1 shared publication
Latest Publications
- Open Access
- 19 January 2026
- Published by Springer Nature in Discover Public Health
- Vol. 23 (1) , 54
Knowledge, attitudes and practices of antibiotic use among students in a Ghanaian tertiary institution
- 19 January 2026
- Published by Springer Nature in Discover Public Health
- Vol. 23 (1) , 54
Open AccessKnowledge, attitudes and practices of antibiotic use among students in a Ghanaian tertiary institution
- Open Access
Prevalence of Common Respiratory Viruses in Children: Insights from Post-Pandemic Surveillance
Introduction: The COVID-19 pandemic has significantly affected healthcare systems worldwide, impacting the occurrence and management of respiratory illnesses. This has also influenced respiratory infections’ role in childhood mortality. Surveillance of common respiratory viruses in Ghana is limited, making it crucial to assess the prevalence of respiratory viral infections, particularly in children, in the post-pandemic era. This study provides data on the prevalence of respiratory viruses and the associated risk factors in children aged 5 or younger in an urban paediatric hospital setting. Methods: The study was a cross-sectional study with a convenience sampling method, conducted in four health facilities: Asokwa Children’s Hospital, HopeXchange Medical Centre, University Health Services-KNUST, and Kumasi South Hospital in Kumasi, Ghana, between August 2022 and June 2023. Recruitment was not done in parallel in each hospital. Oropharyngeal swabs were collected from children ≤ 5 years old and screened by RT-qPCR for common respiratory viruses. Results: Out of the 303 patients enrolled in the study, 165 (54.4%) were male, and 122 (40.3%) were aged from 13 to 36 months. The median age of the patients was 19 months. The most common symptoms reported were cough (87.0%), runny nose (87.0%), and fever (72.0%). Respiratory viruses were detected in 100 (33.0%) of the samples, with 36 (12.0%) testing positive for Human metapneumovirus (HMPV), 27 (8.9%) for RSV, and 20 (6.6%) for Human Adenovirus (HAdV). In 8.0% of the cases, multiple viruses were detected, with HAdV being the most common (75.0%). Children under 6 months (AOR: 4.81, 95% CI: 1.20-24.60) had a higher risk of RSV detection compared to children aged 37 to 60 months. Furthermore, it was found that caregivers with tertiary education had a higher risk of HMPV detection (AOR: 6.91, 95% CI: 1.71-47.3). Conclusion: The study’s findings emphasize RSV infection in very young children and the potentially significant role of HMPV in causing respiratory infections among children in Ghana. Active surveillance of common respiratory viruses in healthcare facilities could enhance the management of viral respiratory infection cases in the paediatric population in Ghana.
Open AccessPrevalence of Common Respiratory Viruses in Children: Insights from Post-Pandemic Surveillance
Introduction: The COVID-19 pandemic has significantly affected healthcare systems worldwide, impacting the occurrence and management of respiratory illnesses. This has also influenced respiratory infections’ role in childhood mortality. Surveillance of common respiratory viruses in Ghana is limited, making it crucial to assess the prevalence of respiratory viral infections, particularly in children, in the post-pandemic era. This study provides data on the prevalence of respiratory viruses and the associated risk factors in children aged 5 or younger in an urban paediatric hospital setting. Methods: The study was a cross-sectional study with a convenience sampling method, conducted in four health facilities: Asokwa Children’s Hospital, HopeXchange Medical Centre, University Health Services-KNUST, and Kumasi South Hospital in Kumasi, Ghana, between August 2022 and June 2023. Recruitment was not done in parallel in each hospital. Oropharyngeal swabs were collected from children ≤ 5 years old and screened by RT-qPCR for common respiratory viruses. Results: Out of the 303 patients enrolled in the study, 165 (54.4%) were male, and 122 (40.3%) were aged from 13 to 36 months. The median age of the patients was 19 months. The most common symptoms reported were cough (87.0%), runny nose (87.0%), and fever (72.0%). Respiratory viruses were detected in 100 (33.0%) of the samples, with 36 (12.0%) testing positive for Human metapneumovirus (HMPV), 27 (8.9%) for RSV, and 20 (6.6%) for Human Adenovirus (HAdV). In 8.0% of the cases, multiple viruses were detected, with HAdV being the most common (75.0%). Children under 6 months (AOR: 4.81, 95% CI: 1.20-24.60) had a higher risk of RSV detection compared to children aged 37 to 60 months. Furthermore, it was found that caregivers with tertiary education had a higher risk of HMPV detection (AOR: 6.91, 95% CI: 1.71-47.3). Conclusion: The study’s findings emphasize RSV infection in very young children and the potentially significant role of HMPV in causing respiratory infections among children in Ghana. Active surveillance of common respiratory viruses in healthcare facilities could enhance the management of viral respiratory infection cases in the paediatric population in Ghana.
- Open Access
- 25 May 2022
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 19 (1) , 1-10
Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana
Background: Viral suppression remains the most desired outcome in the management of patients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) and this can be achieved by an effective Antiretroviral Therapy (ART). However, some patients who achieve viral suppression may experience viral rebound with dire consequence. We evaluated viral suppression and rebound and their associated factors among adult patients on ART in Kumasi, Ghana. Methods: This hospital-based retrospective study was conducted at the Komfo Anokye Teaching Hospital in Ghana. We reviewed the medical records of 720 HIV patients on ART. Statistical analyses were performed using SPSS Version 26.0 and GraphPad prism version 8.0. p < 0.05 was considered statistically significant. Results: Proportions of patients with viral suppression and viral rebound were 76.1% and 21.0% respectively. Being diagnosed at WHO stage I [aOR = 11.40, 95% CI (3.54–36.74), p < 0.0001], having good adherence to ART [aOR = 5.09, 95% CI (2.67–9.73), p < 0.0001], taking Nevirapine-based regimen [aOR = 4.66, 95% CI (1.20–18.04), p = 0.0260] and increasing duration of treatment (p < 0.0001) were independently associated with higher odds of viral suppression. However, being diagnosed at WHO stage II (aOR = 7.39, 95% CI 2.67–20.51; p < 0.0001) and stage III (aOR = 8.62, 95% CI 3.16–23.50; p < 0.0001), having poor adherence (aOR = 175.48, 95% CI 44.30–695.07; p < 0.0001), recording baseline suppression value of 20–49 copies/mL (aOR = 6.43, 95% CI 2.72–15.17; p < 0.0001) and being treated with Zidovudine/Lamivudine/Efavirenz (aOR = 6.49, 95% CI 1.85–22.79; p = 0.004) and Zidovudine/Lamivudine/Nevirapine (aOR = 18.68, 95% CI 1.58–220.90; p = 0.02) were independently associated with higher odds of viral rebound. Conclusion: Approximately 76% viral suppression rate among HIV patients on ART in Kumasi falls below the WHO 95% target by the year 2030. Choice of ART combination, drug adherence, WHO clinical staging and baseline viral load are factors associated with suppression or rebound. These clinical characteristics of HIV patients must be monitored concurrently with the viral load.
- 25 May 2022
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 19 (1) , 1-10
Open AccessFactors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana
Background: Viral suppression remains the most desired outcome in the management of patients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) and this can be achieved by an effective Antiretroviral Therapy (ART). However, some patients who achieve viral suppression may experience viral rebound with dire consequence. We evaluated viral suppression and rebound and their associated factors among adult patients on ART in Kumasi, Ghana. Methods: This hospital-based retrospective study was conducted at the Komfo Anokye Teaching Hospital in Ghana. We reviewed the medical records of 720 HIV patients on ART. Statistical analyses were performed using SPSS Version 26.0 and GraphPad prism version 8.0. p < 0.05 was considered statistically significant. Results: Proportions of patients with viral suppression and viral rebound were 76.1% and 21.0% respectively. Being diagnosed at WHO stage I [aOR = 11.40, 95% CI (3.54–36.74), p < 0.0001], having good adherence to ART [aOR = 5.09, 95% CI (2.67–9.73), p < 0.0001], taking Nevirapine-based regimen [aOR = 4.66, 95% CI (1.20–18.04), p = 0.0260] and increasing duration of treatment (p < 0.0001) were independently associated with higher odds of viral suppression. However, being diagnosed at WHO stage II (aOR = 7.39, 95% CI 2.67–20.51; p < 0.0001) and stage III (aOR = 8.62, 95% CI 3.16–23.50; p < 0.0001), having poor adherence (aOR = 175.48, 95% CI 44.30–695.07; p < 0.0001), recording baseline suppression value of 20–49 copies/mL (aOR = 6.43, 95% CI 2.72–15.17; p < 0.0001) and being treated with Zidovudine/Lamivudine/Efavirenz (aOR = 6.49, 95% CI 1.85–22.79; p = 0.004) and Zidovudine/Lamivudine/Nevirapine (aOR = 18.68, 95% CI 1.58–220.90; p = 0.02) were independently associated with higher odds of viral rebound. Conclusion: Approximately 76% viral suppression rate among HIV patients on ART in Kumasi falls below the WHO 95% target by the year 2030. Choice of ART combination, drug adherence, WHO clinical staging and baseline viral load are factors associated with suppression or rebound. These clinical characteristics of HIV patients must be monitored concurrently with the viral load.